[1] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2] RUSTGI A K,EL-SERAG H B.Esophageal carcinoma[J].N Engl J Med,2014,371(26):2499-2509.
[3] STEYERBERG E W,NEVILLE B,WEEKS J C,et al.Referral patterns,treatment choices,and outcomes in locoregional esophageal cancer:a population-based analysis of elderly patients[J].J Clin Oncol,2007, 25(17):2389-2396.
[4] 陆斌,瞿彩平,孙征,等.卡培他滨维持治疗晚期食管-胃交界处腺癌的临床观察[J].东南大学学报(医学版),2017,36(1):86-89.
[5] COOPER J S,GUO M D,HERSKOVIC A.Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective radomized trial(RTOG85-01).Radiation Therapy Oncology Group[J].J Am Med Assoc, 1999,281(17):1623-1627.
[6] PANDE A U,IYER R V,RANI A,et al.Epidermal growth factor receptor-directed therapy in esophageal cancer[J].Oncology,2007,73(5-6):281-289.
[7] KONO K,MIMURA K,FUJII H,et al.Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma[J].Ann Thorac Cardiovasc Surg,2012,18(6):506-513.
[8] CROMBET R T,RAK J,PEREZ R,et al.Antiproliferative,antiangiogenic and proapoptotic activity of h-R3:a humanized anti-EGFR antibody[J].Int J Cancer,2002,101(6):567-575.
[9] DE CASTRO-JUNIOR G,SEGALLA J G,DE AZEVEDO S J,et al.A randomised phase Ⅱ study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer:NICE trial[J].Eur J Cancer,2018,88(1):21-30.
[10] RAMOS-SUZARTE M,LORENZO-LUACES P,LAZO N G,et al.Treatment of malignant,non-resectable,epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy[J].Cancer Biol Ther,2012,13(8):600-605.
[11] ZHAO L,HE LR,XI M,et al.Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3[J].J Transl Med,2012,10:249-257.
[12] 翟医蕊,惠周光,梁军,等.同步尼妥珠单抗联合放化疗治疗不可切除局部晚期食管鳞癌的疗效分析[J].中国临床医生杂志,2019, 47(9):1052-1055.
[13] LIANG J,MINGYAN E,WU G,et al.Nimotuzumab combined with radiotherapy for esophageal cancer:preliminary study of a Phase ii clinical trial[J].Onco Targets Ther,2013,6:1589-1596.
[14] ZHANG P,XI M,ZHAO L,et al.Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma[J].PLoS One,2014,9(8):e105720.
[15] ISHIDA K,ANDO N,YAMAMOTO S,et al.Phase Ⅱ study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus:a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial(JCOG9516)[J].Jpn J Clin Oncol,2004,34(10):615-619.
[16] HAN J,ZHU W,TU C,et al.Clinical study of concurrent chemoradiotherapy or radiotherapy alone for esophageal cancer patients with positive lymph node metastasis[J].Tumori,2012,98(1):60-65.
[17] SEMRAU R,HERZOG S L,VALLBÖHMER D,et al.Radiotherapy in elderly patients with inoperable esophageal cancer.Is there a benefit[J].Strahlenther Onkol,2012,188(3):226-232.
[18] TAKEUCHI S,OHTSU A,DOI T,et al.A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer[J].Am J Clin Oncol,2002,30(6):607-611. |